Seminars in Oncology
Volume 33 , Pages 12-16 , April 2006

Management of Platinum-Sensitive Recurrent Ovarian Cancer

  • Jacobus Pfisterer

      Affiliations

    • Klinik für Gynäkologie und Geburtshilfe Campus Kiel, Universitätsklinikum Schleswig-Holstein, Germany
    • Prof Pfisterer has received speaker’s honoraria from Eli Lilly & Co. Dr Ledermann has served as a medical consultant and invited speaker for Eli Lilly & Co.
    • Corresponding Author InformationAddress reprint requests to Prof Dr Jacobus Pfisterer, Klinik für Gynäkologie und Geburtshilfe Campus Kiel, Universitätsklinikum Schleswig-Holstein 24105 Kiel, Germany.
    • ,
  • Jonathan A. Ledermann

      Affiliations

    • Cancer Research UK and The University College of London Cancer Trials Centre, Department of Oncology, University College London, London, United Kingdom.

References 

  1. du Bois A , Lück HJ , Meier W , et al.   A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer . J Natl Cancer Inst . 2003;95:1320–1329
  2. Ozols RF , Bundy BN , Greer BE , et al.   Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer (A Gynecologic Oncology Group study) . J Clin Oncol . 2003;21:3194–3200
  3. Markman M , Rothman R , Hakes T , et al.   Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin . J Clin Oncol . 1991;9:389–393
  4. Gore ME , Fryatt I , Wiltshaw E , et al.   Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds . Gynecol Oncol . 1990;36:207–211
  5. ten Bokkel Huinink W , Gore M , Carmichael J , et al.   Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer . J Clin Oncol . 1997;15:2183–2193
  6. Gordon AN , Fleagle JT , Guthrie D , et al.   Recurrent epithelial ovarian carcinoma (A randomized phase III study of pegylated liposomal doxorubicin versus topotecan) . J Clin Oncol . 2001;19:3312–3322
  7. Taylor AE , Wiltshaw E , Gore ME , et al.   Long-term follow-up of the first randomized study of cisplatin versus carboplatin for advanced epithelial ovarian cancer . J Clin Oncol . 1994;12:2066–2070
  8. Dizon DS , Hensley ML , Poynor EA , et al.   Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma (Application toward a dynamic disease state model of ovarian cancer) . J Clin Oncol . 2002;20:1238–1247
  9. du Bois A , Lück HJ , Pfisterer J , et al.   Second-line carboplatin and gemcitabine in platinum-sensitive ovarian cancer – A dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group . Ann Oncol . 2001;12:1115–1120
  10. Bolis G , Scarfone G , Giardina G , et al.   Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer . Gynecol Oncol . 2001;81:3–9
  11. Parmar MK , Ledermann JA , Colombo N , et al.   Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer (The ICON 4/AGO-OVAR-2.2 trial) . Lancet . 2003;361:2099–2106
  12. Metzinger DS , Taylor DD . Gercel-Taylor C (Induction of p53 and drug resistance following treatment with cisplatin or paclitaxel in ovarian cancer cell lines) . Cancer Lett . 2005; (epub ahead of print)
  13. Lund B , Hansen OP , Theilade K , et al.   Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients . J Natl Cancer Inst . 1994;86:1530–1533
  14. Lund B , Neijt JP . Gemcitabine in cisplatin-resistant ovarian cancer . Semin Oncol . 1996;23(suppl 10):72–76
  15. Shapiro JD , Millward MJ , Rischin D , et al.   Activity of gemcitabine in patients with advanced ovarian cancer (Responses seen following platinum and paclitaxel) . Gynecol Oncol . 1996;63:89–93
  16. Pfisterer J , Plante M , Vergote I , et al.   Gemcitabine/carboplatin vs. carboplatin in platinum sensitive recurrent ovarian cancer (results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO-OVAR, the NCIC CTG and the EORTC GCG) . J Clin Oncol . 2004;22(suppl):5005; (abstr)
  17. Pfisterer J , Vergote I , du Bois A , et al.   Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer . Int J Gynecol Cancer . 2005;15(suppl 1):36–41
  18. Calvert AH , Newell DR , Gumbrell LA , et al.   Carboplatin dosage (Prospective evaluation of a simple formula based on renal function) . J Clin Oncol . 1989;7:1748–1756
  19. Jelliffe RW . Letter: Creatinine clearance: bedside estimate . Ann Intern Med . 1973;79:604–605

PII: S0093-7754(06)00119-9

doi: 10.1053/j.seminoncol.2006.03.012

Seminars in Oncology
Volume 33 , Pages 12-16 , April 2006

Article Tools

* Image Usage & Resolution